Last €124.05 EUR
Change Today -0.80 / -0.64%
Volume 1.4K
As of 11:35 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

sartorius stedim biotech (DIM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/14 - €153.50
52 Week Low
10/10/13 - €105.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sartorius stedim biotech (DIM) Related Businessweek News

No Related Businessweek News Found

sartorius stedim biotech (DIM) Details

Sartorius Stedim Biotech S.A. provides various equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry worldwide. The company’s integrated solutions covering fermentation, filtration, purification, fluid management, process control, and lab technologies support the biopharmaceutical industry to develop and produce drugs. Its products include filter membranes, and single-use and reusable bioreactors, single-use bags, tubing, connectors, and containers, as well as filtration systems, filter integrity testing equipment, and sophisticated services. The company also offers laboratory instruments, including weighing, quality control, lab water purification, liquid handling, cell cultivation, filtration, and purification products, as well as spare parts and consumables. It serves biopharmaceutical, pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

3,628 Employees
Last Reported Date: 07/23/14
Founded in 1870

sartorius stedim biotech (DIM) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: €922.0K
Executive Vice President of Operations & IT, ...
Total Annual Compensation: €552.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: €549.0K
Execurtive Vice President of Marketing, Sales...
Total Annual Compensation: €568.0K
Compensation as of Fiscal Year 2013.

sartorius stedim biotech (DIM) Key Developments

Sartorius Stedim Biotech S.A. Reports Unaudited Earnings Results for the First Half of 2014; Provides Earnings Guidance for the Year 2014

Sartorius Stedim Biotech S.A. reported unaudited earnings results for the first half of 2014. For the six months period, the company reported sales revenue of EUR 324.1 million compared to EUR 292.6 million a year ago. EBITDA was EUR 73.8 million compared to EUR 67.4 million a year ago. EBITA was EUR 62.5 million compared to EUR 57.4 million a year ago. Net profit was EUR 40.7 million or EUR 2.65 per share compared to EUR 38.0 million or EUR 2.47 per share a year ago. Underlying EBITDA rose 9.5% to EUR 73.8 million. Underlying earnings per share were EUR 2.65, up from EUR 2.47 in the first six months of 2013. Based on company’s strong first-half performance, management confirmed and specified its full-year forecast for 2014. Sales growth in constant currencies is expected to reach the upper end of the 11% to 14% range, while the underlying EBITDA margin is forecasted to rise to approx. 23.5% in constant currencies. The Capex ratio is projected to be in the range of 6% to 8%.

Sartorius Stedim Biotech S.A., H1 2014 Earnings Call, Jul 22, 2014

Sartorius Stedim Biotech S.A., H1 2014 Earnings Call, Jul 22, 2014

Sartorius Stedim Biotech S.A. Presents at Gilbert Dupont Healthcare Conference, May-13-2014

Sartorius Stedim Biotech S.A. Presents at Gilbert Dupont Healthcare Conference, May-13-2014 . Venue: Paris, France.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIM:FP €124.05 EUR -0.80

DIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corning Inc $20.54 USD -0.11
General Electric Co $26.15 USD -0.28
Pall Corp $80.40 USD -0.61
Thermo Fisher Scientific Inc $121.22 USD -0.59
View Industry Companies

Industry Analysis


Industry Average

Valuation DIM Industry Range
Price/Earnings 28.1x
Price/Sales 3.0x
Price/Book 3.8x
Price/Cash Flow 31.1x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARTORIUS STEDIM BIOTECH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at